Momenta Pharmaceuticals, Inc.
MNTA
MNTA was delisted on the 30th of September, 2020.
164 hedge funds and large institutions have $1.21B invested in Momenta Pharmaceuticals, Inc. in 2017 Q2 according to their latest regulatory filings, with 16 funds opening new positions, 82 increasing their positions, 41 reducing their positions, and 14 closing their positions.
794% more call options, than puts
Call options by funds: $3.33M | Put options by funds: $373K
100% more repeat investments, than reductions
Existing positions increased: 82 | Existing positions reduced: 41
38% more capital invested
Capital invested by funds: $873M → $1.21B (+$336M)
14% more first-time investments, than exits
New positions opened: 16 | Existing positions closed: 14
1% more funds holding
Funds holding: 162 → 164 (+2)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
+$76M |
| 2 |
AC
Armistice Capital
New York
|
+$12.5M |
| 3 |
BlackRock
New York
|
+$9.53M |
| 4 |
Acadian Asset Management
Boston,
Massachusetts
|
+$8.09M |
| 5 |
Renaissance Technologies
New York
|
+$7.9M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DCM
Discovery Capital Management
South Norwalk,
Connecticut
|
-$27.2M |
| 2 |
NI
Numeric Investors
Boston,
Massachusetts
|
-$13.6M |
| 3 |
FCMI
Foresite Capital Management III
Larkspur,
California
|
-$5.75M |
| 4 |
TCM
Tekla Capital Management
Boston,
Massachusetts
|
-$5.35M |
| 5 |
SAM
Senzar Asset Management
New York
|
-$4.18M |
MNTA Hedge Fund Activity: Q2 2017 in Review
164 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Momenta Pharmaceuticals, Inc. (MNTA) for Q2 2017, worth a combined $1.21B — up 38% from $873M a quarter earlier.
Buyers outnumbered sellers: 16 funds opened new MNTA positions and 14 closed out — a net gain of 2 holders — while 82 added to existing stakes and 41 trimmed.
The largest buyer was Wellington Management Group, opening a new position worth an estimated $76M. The largest seller was Discovery Capital Management, cutting an estimated $27.2M.
- 164 institutional investors held Momenta Pharmaceuticals, Inc. (MNTA) as of Q2 2017, up from 162 in Q1 2017.
- Funds reported $1.21B of Momenta Pharmaceuticals, Inc. stock for Q2 2017, up 38% quarter-over-quarter.
- 16 funds opened new Momenta Pharmaceuticals, Inc. positions in Q2 2017 and 14 closed out, a net change of +2 holders.
- The largest Momenta Pharmaceuticals, Inc. buyer in Q2 2017 was Wellington Management Group, an estimated $76M added.
- The largest Momenta Pharmaceuticals, Inc. seller in Q2 2017 was Discovery Capital Management, an estimated $27.2M sold.
Based on aggregated 13F filings for Q2 2017.